"The Next Best Way To Block Generics" May Be Novo's Patent Use Code Switch
Executive Summary
The generic industry has lined up against Novo Nordisk's maneuver to keep Caraco Pharmaceuticals from getting approval of a generic version of its diabetes drug Prandin
You may also be interested in...
Caraco Seeks Supreme Court Intervention In Its Prandin Patent Use Code Battle With Novo
Caraco asks the Supreme Court to decide whether it can file a counterclaim opposing Novo's revision of its patent use code for the diabetes drug.
Patent Use Codes May Still Block Generics As FDA Looks For Alternatives
FDA is assessing ways to alter how it handles patent use codes following charges they are being used to derail the approval of generics, but a straightforward solution has so far eluded the agency.
Patent Use Codes May Still Block Generics As FDA Looks For Alternatives
FDA is assessing ways to alter how it handles patent use codes following charges they are being used to derail the approval of generics, but a straightforward solution has so far eluded the agency.